Insulin-like growth factor-1 in early-onset coronary artery disease: Insights into the pathophysiology of atherosclerosis

Lorenzo, Andrea De; Moreira, Annie Seixas Bello; Souza, Elaine G.; Oliveira, Gláucia Maria Moraes de

doi:10.1016/j.ijcard.2015.04.032

Cited by 7 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In possibly the largest observational study on the relation of IGF-1 to CAD in 10,600 coronary-disease free subjects in the PRIME study, Ruidavets et al [71] found that baseline IGF-1 level was significantly lower in subjects developing an acute coronary syndrome, and that subjects in the highest quartile of IGF-1 distribution had a 55% reduction in the relative risk of developing myocardial infarction [71]. Similarly, De Leronzo et al [72], in a small study on 36 patients, showed significantly lower IGF-1 level in patients with early-onset CAD [72].…”

Section: <Coronary Artery Disease (Cad)>mentioning

confidence: 97%

IGF-1 and cardiovascular disease

Higashi

Gautam

Delafontaine

et al. 2019

Growth Hormone & IGF Research

View full text Add to dashboard Cite

Atherosclerosis is an inflammatory arterial pathogenic condition, which leads to ischemic cardiovascular diseases, such as coronary artery disease and myocardial infarction, stroke, and peripheral arterial disease. Atherosclerosis is a multifactorial disorder and its pathophysiology is highly complex. Changes in expression of multiple genes coupled with environmental and lifestyle factors initiate cascades of adverse events involving multiple types of cells (e.g. vascular endothelial cells, smooth muscle cells, and macrophages). IGF-1 is a pleiotropic factor, which is found in the circulation (endocrine IGF-1) and is also produced locally in arteries (endothelial cells and smooth muscle cells). IGF-1 exerts a variety of effects on these cell types in the context of the pathogenesis of atherosclerosis. In fact, there is an increasing body of evidence suggesting that IGF-1 has beneficial effects on the biology of atherosclerosis. This review will discuss recent findings relating to clinical investigations on the relation between IGF-1 and cardiovascular disease and basic research using animal models of atherosclerosis that have elucidated some of the mechanisms underlying atheroprotective effects of IGF-1.

show abstract

Section: <Coronary Artery Disease (Cad)>mentioning

confidence: 97%

IGF-1 and cardiovascular disease

Higashi

Gautam

Delafontaine

et al. 2019

Growth Hormone & IGF Research

View full text Add to dashboard Cite

show abstract

“…IGF‐1 reduces the progression of atherosclerosis, and in cross‐sectional studies, low circulating IGF‐1 is associated with increased risk of ischemic stroke . In humans, low levels of IGF‐1 are associated with stroke risk factors such as diabetes, hypertension, and coronary artery disease . Previous studies regarding stroke patients have suggested that low IGF‐1 levels in the circulation are related with higher stroke severity, poor outcome, and less rates of survival after stroke .…”

Section: Introductionmentioning

confidence: 99%

“…2 In humans, low levels of IGF-1 are associated with stroke risk factors such as diabetes, hypertension, and coronary artery disease. [3][4][5] Previous studies regarding stroke patients have suggested that low IGF-1 levels in the circulation are related with higher stroke severity, poor outcome, and less rates of survival after stroke. [6][7][8][9] De Smedt et al (2011) suggested that high serum IGF-I levels after the onset of ischemic stroke are associated with neurological recovery and a better functional outcome.…”

Section: Introductionmentioning

confidence: 99%

The relation between insulin‐like growth factor 1 levels and risk of depression in ischemic stroke

Zhang

Wang

Kuang

2017

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…Several other studies confirmed a relationship between elevated IGF-1 levels and a decreased prevalence or incidence of CAD ( 156 – 158 ). Additionally, it was found that individuals with early-onset CAD had considerably lower IGF-1 levels ( 157 ).…”

Section: Effects Of Igf-1 In Pathophysiological Conditionsmentioning

confidence: 99%

New insights on the cardiovascular effects of IGF-1

et al. 2023

View full text Add to dashboard Cite

IntroductionCardiovascular (CV) disorders are steadily increasing, making them the world’s most prevalent health issue. New research highlights the importance of insulin-like growth factor 1 (IGF-1) for maintaining CV healthMethodsWe searched PubMed and MEDLINE for English and non-English articles with English abstracts published between 1957 (when the first report on IGF-1 identification was published) and 2022. The top search terms were: IGF-1, cardiovascular disease, IGF-1 receptors, IGF-1 and microRNAs, therapeutic interventions with IGF-1, IGF-1 and diabetes, IGF-1 and cardiovascular disease. The search retrieved original peer-reviewed articles, which were further analyzed, focusing on the role of IGF-1 in pathophysiological conditions. We specifically focused on including the most recent findings published in the past five years.ResultsIGF-1, an anabolic growth factor, regulates cell division, proliferation, and survival. In addition to its well-known growth-promoting and metabolic effects, there is mounting evidence that IGF-1 plays a specialized role in the complex activities that underpin CV function. IGF-1 promotes cardiac development and improves cardiac output, stroke volume, contractility, and ejection fraction. Furthermore, IGF-1 mediates many growth hormones (GH) actions. IGF-1 stimulates contractility and tissue remodeling in humans to improve heart function after myocardial infarction. IGF-1 also improves the lipid profile, lowers insulin levels, increases insulin sensitivity, and promotes glucose metabolism. These findings point to the intriguing medicinal potential of IGF-1. Human studies associate low serum levels of free or total IGF-1 with an increased risk of CV and cerebrovascular illness. Extensive human trials are being conducted to investigate the therapeutic efficacy and outcomes of IGF-1-related therapy.DiscussionWe anticipate the development of novel IGF-1-related therapy with minimal side effects. This review discusses recent findings on the role of IGF-1 in the cardiovascular (CVD) system, including both normal and pathological conditions. We also discuss progress in therapeutic interventions aimed at targeting the IGF axis and provide insights into the epigenetic regulation of IGF-1 mediated by microRNAs.

show abstract

Insulin-like growth factor-1 in early-onset coronary artery disease: Insights into the pathophysiology of atherosclerosis

Cited by 7 publications

References 10 publications

IGF-1 and cardiovascular disease

IGF-1 and cardiovascular disease

The relation between insulin‐like growth factor 1 levels and risk of depression in ischemic stroke

New insights on the cardiovascular effects of IGF-1

Contact Info

Product

Resources

About